ursodeoxycholic acid + methylprednisolone

Ursodeoxycholic acid + methylprednisolone is a combination therapy consisting of ursodeoxycholic acid (UDCA), a hydrophilic bile acid, and methylprednisolone, a synthetic glucocorticoid corticosteroid. UDCA acts primarily by reducing the cytotoxicity of bile acids, promoting choleresis, and exerting anti-inflammatory effects in the liver. Methylprednisolone suppresses immune responses and inflammation by modulating gene expression through the glucocorticoid receptor. This combination has been investigated for use in autoimmune liver diseases such as primary biliary cholangitis (PBC) and drug-induced liver injury (DILI), particularly in patients who have an insufficient response to monotherapy with either agent. The rationale for combining these drugs is to leverage both the cytoprotective/anti-cholestatic effects of UDCA and the immunosuppressive/anti-inflammatory actions of methylprednisolone to improve clinical outcomes[1][2][3][4].